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22q11-deletion (DiGeorge/velocardiofacial) syndrome (22q11DS) is modeled by mutation of murine transcription factor Tbx1. As part of
efforts to identify transcriptional targets of Tbx1, we analyzed the transcriptome of the pharyngeal region of Df1/+;Tbx1+/ embryos at 9.5
days of embryonic development using two independent microarray platforms. In this model, embryos are null for Tbx1, with hemizygosity of
genes in cis with Tbx1 on one chromosome providing a positive control for array sensitivity. Reduced mRNA levels of genes deleted from
Df1 were detected on both platforms. Expression level filtering and statistical analysis identified several genes that were consistently
differentially expressed between mutant and wild type embryos. Real-time quantitative PCR and in situ hybridization validated diminished
expression of Pax9 and Gcm2, genes known to be required for normal thymus and parathyroid gland morphogenesis, whereas Pax1, Hoxa3,
Eya1, and Foxn1, which are similarly required, were not down-regulated. Gbx2, a gene required for normal arch artery development, was
down-regulated specifically in the pharyngeal endoderm and the posterior part of pharyngeal arch 1, and is a potential point of cross talk
between the Tbx1 and Fgf8 controlled pathways. These experiments highlight which genes and pathways potentially affected by lack of
Tbx1, and whose role may be explored further by testing for epistasis using mouse mutants.
D 2005 Elsevier Inc. All rights reserved.Keywords: Expression microarray; DiGeorge syndrome; 22q11 deletion; Pharyngeal development Tbx1Introduction
Deletion 22q11.2 (22q11DS) is the most common micro-
deletion syndrome in man with an incidence of approx-
imately 1:4000 live births (Scambler, 2003). The major
malformations include congenital heart defects such as
truncus arteriosus (TA) and interrupted aortic arch type B
(IAA-B), hypo/aplasia of the parathyroid gland, hypo/aplasia
of the thymus gland, and craniofacial dysmorphism. Velo-
pharyngeal insufficiency is also a common problem, result-
ing in the diagnosis of velo-cardio-facial syndrome (VCFS);
DiGeorge sequence is another diagnosis commonly made in
affected individuals (Scambler, 2003). Genetic studies,0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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box transcription factor, as the major gene haploinsufficient
in the syndrome (Baldini, 2004; Epstein, 2001). Additional
genes may play a modifying role, or have a major role in
development of some features such as the cognitive and
behavioral problems reported in this condition (Paylor et al.,
2001). However, in order to understand the developmental
basis of 22q11DS, most attention has been directed at
understanding the contribution of Tbx1 to embryogenesis.
Tbx1 is expressed in the mesoderm of the first pharyngeal
pouch and the pharyngeal endoderm (PE) from embryonic
day (E)8.0 (Garg et al., 2001; Lindsay et al., 2001). At
E9.5, expression is seen throughout the PE and is strongest
in the third pouch area. At E10.5 when the fourth pouch has
formed, Tbx1 is most strongly expressed in the posterior
regions of the PE. At E9.5, Tbx1 is expressed in the
mesenchyme underlying the hindbrain, but is not expressed85 (2005) 554 – 569
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the anterior (secondary heart field). At E9.5, Tbx1 is
expressed in the muscular wall of the outflow tract and later
at E11.5 in the endothelial and subendothelial cells. By
E11.5, pharyngeal expression is largely limited to the fourth
pouch.
The first mouse model of 22q11DS was provided by an
engineered deletion of mouse chromosome 16, Df1, which
reduces 22 genes to hemizygosity (Lindsay et al., 1999).
Investigations have shown that the embryological pheno-
type of Tbx1+/ mutants is indistinguishable from that of
deletion mutants (Df1 or Lgdel), that the phenotype of Df1
mutants can be rescued by a transgene containing Tbx1, and
that Df1/+;Tbx1+/ transheterozygotes have embryonic
phenotypes indistinguishable from Tbx1/ embryos (Lind-
say et al., 2001; Merscher et al., 2001; Vitelli et al., 2002a).
Tbx1+/ and Df1/+ embryos have a fully penetrant
hypoplasia of the fourth pharyngeal arch artery at E10.5
which may recover by birth, so that approximately 20% of
heterozygotes have a congenital heart defect such as an IAA-
B, a malformation typical of 22q11DS (Lindsay and Baldini,
2001; Lindsay et al., 2001). Tbx1/ and Df1/+;Tbx1+/
mice have an unsegmented pharynx, with a hypoplastic 2nd
and no evident 3rd and 4th pouches, resulting in aplasia of the
thymus and parathyroid glands. The null mice also have a
cleft palate, and ear defects. Late stage null embryos have a
common arterial trunk (Jerome and Papaioannou, 2001). In
one targeted mutant, Tbx1 coding sequences were replaced
by a h-galactosidase gene, and staining of embryos revealed
that Tbx1 lineage Tbx1/cells are still present in null
mutants (Lindsay et al., 2001; Vitelli et al., 2002a).
Tbx1 is regulated in part by Shh, which appears to act via
Foxa2 and perhaps related Foxa and Foxc transcription
factors (Yamagishi et al., 2003). In the pharyngeal meso-
derm, Foxa2 is selectively down-regulated in Tbx1 hypo-
morphic mutants suggesting a region-specific feedback loop
(Hu et al., 2004). Tbx1 hypomorphs also show an increased
susceptibility of the cardiac outflow tract to the effects of
reduced Tbx1 gene dosage (Hu et al., 2004; Xu et al., 2004).
Tbx1 itself can regulate Fgf8 and Fgf10 expression, and
Fgf8+/;Tbx1+/ double heterozygotes have more severe
cardiovascular defects than Tbx1+/ mutants alone (Vitelli
et al., 2002b). Thus, while some of the targets of Tbx1 have
been identified in these experiments, presumably many
others remain to be identified.
In this paper, we report a microarray analysis of the
transcriptome of Tbx1/ embryos at E9.5 which is aimed
at identifying genes with quantitatively changed expression
when compared to wild type. Differential expression of
molecular markers may indicate a direct target of Tbx1, or
an indirect target whose altered expression gives clues as to
developmental defects in particular tissues or cell popula-
tions. Genes with a known or plausible role in the genesis of
structures affected in Tbx1/ mice and 22q11DS patients
were analyzed further, by real-time quantitative PCR
(RTQPCR) to corroborate the array data, and in situhybridization to assess qualitative alterations of expression,
relative quantitative differences between expression zones,
and how far these might be attributable to anatomical
disruption in the null mutants as opposed to a change with
potentially more biologically relevant effect. As Tbx1 is a
transcriptional activator (Xu et al., 2004; Ataliotis et al.,
2005), we concentrated on down-regulated genes. We
identified Pax9, Gcm2, and Gbx2 as quantitatively reduced
in expression and suggest that these genes represent good
candidates for Tbx1 target genes, or are expressed in Tbx1-
expressing cell lineages absent or underrepresented in null
mutant embryos.Materials and methods
Mouse strains, breeding, and genotyping
The generation of Df1/+ and Tbx1+/ mutant mice has
been described (Lindsay et al., 1999, 2001). Mutants were
maintained on a mixed C57Bl/6 background. Df1/+ and
Tbx1+/ mice were inter-crossed to generate transheterozy-
gous mutants. Genotyping of embryos was carried out by
PCR analysis of yolk sac or tail tip genomic DNA as
described previously (Lindsay et al., 1999, 2001). Embryos
were obtained from timed mated females and staged by
somite counting.
RNA extraction, amplification, and hybridization of
microarray probes
The pharyngeal region was dissected out from five E9.5
Df1/+;Tbx1+/ and five somite stage-matched wild type
mouse embryos; this region included the major Tbx1-
expressing tissues as described above. The neural tube
was dissected away to reduce the effects from dilution by
non-Tbx1-expressing cells. The tissue was homogenized in
800 Al TRIzol (Invitrogen) and RNA extracted according to
the manufacturer’s protocol. After analysis on an Agilent
Bioanalyzer, one wild type RNA preparation was rejected as
marginally degraded. Each entire RNA sample was ampli-
fied using the MessageAmpi aRNA Kit (Ambion),
according to the manufacturer’s instructions. For generation
of targets to be hybridized with MGU74Av2 GeneChip
arrays (Affymetrix Inc., Santa Clara, California), a second
round of amplification was then carried out using 2 Ag of
first round aRNA to synthesize double-stranded cDNA, and
incorporating biotin-11-CTP (Enzo Biochemicals) and bio-
tin-16-UTP (Roche Molecular Biochemicals) during the
subsequent transcription step. After both first and second
rounds of transcription, samples were treated with DNAseI
to remove contaminating DNA. For targets to be hybridized
with CodeLink Bioarrays (Amersham Biosciences), double
stranded cDNA was generated from first round aRNA as
above, then biotinylated target cRNAwas transcribed as per
the CodeLink Expression Bioarray System protocol (avail-
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com). Biotinylated target aRNAs were hybridized to either
MGU74Av2 GeneChipR arrays (Affymetrix) or CodeLink
Mouse Uniset 1 Bioarrays (Amersham Biosciences) follow-
ing standard procedures (http://www.affymetrix.com, and
the Amersham Biosciences website, as above).
Data analysis (CodeLink Mouse Uniset 1 Bioarrays)
These arrays allow the analysis of 9991 genes, each
represented by a single oligonucleotide. After imaging on
an Axon scanner, the signal intensity at each probe was
calculated. Intensity was defined as the sum of the pixel
signals in the area of interest minus the scaled 2-pixel
median background. The intensities were then median-
normalized by calculating the median of all spots except
for the control probes and blanks and dividing each spot
intensity by the median value. After median normali-
zation, the negative control threshold was calculated using
a set of pre-determined negative controls. The correlation
coefficient was calculated for iterative pairwise compari-
sons of each wild type array and, separately, each
experimental array as the Pearson product moment
correlation coefficient.
Data analysis (Affymetrix GeneChip MGU74Av2 arrays)
The MGU74Av2 arrays enable the analysis of 12,488
transcripts including all sequences in the Mouse Unigene
database (Build 74) and additional EST clusters, with each
transcript being represented by 16 pairs of oligonucleotide
probes (25mers). One of each pair of 25mers contains a
single mis-match. The microarrays were scanned using a
confocal argon– ion laser. The raw image data were
analyzed using Microarray Analysis Suite version 5.0
software, with the data for each chip being normalized to
a target intensity value of 100. The scaling factors used to
normalize the target values for the 9 chips used were within
3-fold of each other (range 0.311–0.724). The arrays used
demonstrated control parameters for raw Q and background
that were within recommended limits (raw Q < 4, back-
ground < 100) although the 3V/5V beta-actin and GAPDH
ratios were higher than the recommended limit of 3. This
was likely due to the amplification process leading to the
generation of targets skewed to the 3Vend. Therefore, the 3V/
Middle probe set ratio (3V/M) was also calculated for
GAPDH, as this was considered more likely to give a
realistic indication of the reliability of the microarray data.
The 3V/M ratio was <2 for all the chips.
Genespring analysis
Genespring software version 4.2.1 (Silicon Genetics,
Inc., Redwood City, California) was used for the compar-
ison of wild type and mutant arrays. Per chip normalization
was carried out for both types of arrays, using the 50thpercentile of all measurements (if above negative control
threshold) as a positive control for each sample. Measure-
ments for each gene were divided by this synthetic positive
control. This was followed by per gene normalization, for
which all wild type samples were normalized to 1, and all
mutant samples were normalized to the wild type samples.
The data from the MGU74Av2 arrays were then filtered to
exclude genes with signals below the minimum control
strength, and genes giving a detection P value of less than
0.1 in 5 out of 9 chips (the latter filter excludes genes which
show a high degree of hybridization to the mis-match
oligonucleotides on the arrays i.e. non-specific hybrid-
ization). For both types of arrays, the filtered normalized
data were then analyzed to identify genes showing relative
normalized expression of <0.8 or >1.2 on at least four out of
five chips hybridized with mutant target. The resulting gene
lists were statistically analyzed using the Wilcoxon–Mann–
Whitney test, with a P value cut-off of 0.05, and applying
the Benjamini and Hochberg False Discovery multiple
testing correction. The data presented in tabular form in
Results show the mean relative values for genes on the 5
mutant chips. Functional categories for genes were assigned
using GO terms from the Gene Ontology Consortium
(www.geneontology.org).
Quantitative real-time PCR
For validation of the microarray results, aRNA from pools
of wild type and pools of Df1/+;Tbx1+/ embryos was
synthesized. 1 Ag of pooled wild type or mutant aRNA was
reverse transcribed using Superscript II (Invitrogen) according
to the manufacturer’s instructions, in a total volume of 20 Al.
The resulting cDNA was diluted 1:5 (1:250 when measuring
GAPDH). RTQPCR was performed using SYBRGreen for
the detection of fluorescence during amplification. Each
amplification reaction contained 10 Al of Quantitect SYBR
Green PCR master mix (Qiagen), 0.2 Ag each of forward and
reverse primers, and 1 Al diluted cDNA in a total volume of
20 Al. All primers were designed with annealing temperatures
of 57–59-C (sequences available on request). PCR conditions
were 95-C for 15 min, followed by 40 cycles of 95-C for 30 s,
57–59-C for 30 s, and 72-C for 30 s. For genes except Fhl2,
Txnrd2, Gbx2, and HoxA3, reactions were performed in
duplicate or quadruplicate in a Smart CyclerR System
(Cepheid) and the data analyzed using the Smart Cycler
software. The other genes were amplified on an ABI7900. At
least 3 separate analyses were carried out for each gene. Melt
curve analysis was performed after each run to check for the
presence of non-specific PCR products and primer dimers. Ct
values were related to copy numbers using standard curves (as
described previously; Roberts et al., 2005). For each gene
examined, a specific PCR fragment was synthesized that was
extended at least 20–30 bp upstream and downstream of the
amplicon generated by the primers used for the RTQPCR.
Normalization was performed using GAPDH as an internal
control as described (Roberts et al., 2005).
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Digoxygenin-labeled RNA probes were prepared by
standard methods. Probes were kindly provided by Alex-
andra Joyner (Gbx2), C. Clare Blackburn (Gcm2, with
permission from David J. Anderson), Rudi Balling (Pax9),
Peter Gruss (Pax1), Ursula Drager (Raldh2), Pin Xu (Eya1)
and Brigid Hogan (FoxA2). HoxA3 riboprobe was synthe-
sized using IMAGE clone 6476230. In situ hybridization
was performed according to previously published methods
(Wilkinson, 1992). At least four somite staged wild type and
mutant embryos were analyzed with each probe. Following
the enzymatic color reaction, embryos were dehydrated
through a graded ethanol series, embedded in paraffin wax
and sectioned at 10–12 Am. Sections were counter-stained
with eosin.
Promoter analysis
Upstream mouse and human genomic sequences for
Gbx2, Pax9, Gcm2, Foxg1, Sox3, and Six2 were obtained
from the UCSC Genome Bioinformatics Site (http://
genome.cse.ucsc.edu/). Sequences were aligned using
mVISTA, a set of programs for comparing DNA sequences
from two or more species (Frazer et al., 2004; Mayor et al.,
2000), available at http://genome.lbl.gov/vista/index.shtml.Table 1
Df1 genes analyzed by microarray
Gene Affymetrix Filtered CodeLink Filtered
ARVCF N 0.534 +
Cdc45l 0.609 + 0.553 +
CdcRel1 1.444  (L) 1.028  (L)
Cln5 0.816  0.776 
Comt 0.822 + 0.456 +
DGCR6 (1) 0.700 + N
DGCR6 (2)* 1.017 
ES2 1.775  (L) 1.367  (L)
Gnb1l N 0.484 +
Gp1bh 0.99  (L) N
Htf9c (1) 0.649 + 0.474 +
Ht9fc (2)* 0.649  (L)
Prodh2 N 0.632 +
Ranbp1 0.609 + 0.590 +
Slc25a (1) 0.784  N
Slc25a (2) 0.804 
T10 0.711 + N
Tbx1 N 0.622 + (L)
Txnrd2 (1) 0.812  0.531 +
Txnrd2 (2) 0.588 +
Ufd1l 1.707  (L) 0.606 +
Affymetrix and CodeLink columns show relative expression on microarray
chips hybridized with Df1/+;Tbx1+/ target (averaged across 5 chips). N
stands for not present on chip. Filtered (+ or ) indicates whether or not the
probe passed quantitative and statistical filtering (see Materials and
methods).
L stands for low signal strength (below detection threshold) and * indicates
poor array probe quality.Results
Microarray analysis of wild type and Df1/+;Tbx1+/
embryos; down-regulation of Df1 genes
Expression profiles of somite-stage matched Df1/+;
Tbx1+/ and wild type embryos were determined by
microarray analysis. Microarray targets were synthesized
from RNA extracted from the major Tbx1-expressing tissues,
namely pharyngeal arches and neighboring tissues, including
mesenchyme underlying the hindbrain. Targets correspond-
ing to individual wild type or mutant embryos were
hybridized with both CodeLink Mouse Uniset 1 Bioarrays
(Amersham Biosciences) and Affymetrix MGU74a Gene-
Chip arrays. For the CodeLink arrays, correlation coeffi-
cients of 0.99 for each pair-wise comparison of the wild type
chips, and 0.98 (0.97–0.99) for pair-wise comparisons of the
mutant chips showed that overall the noise and variability of
the system were low. 7583 genes were above threshold
detection levels on the Codelink arrays and 6696 on the
Affymetrix arrays. GeneSpring software was used to analyze
the microarray data, with gene expression in the wild type
samples being used as a baseline for normalization.
Df1/+;Tbx1+/ transheterozygous rather than Tbx1/
embryos were used so that the haploid genes from the Df1
deleted region would serve as internal controls to test the
sensitivity of the microarray system and alert us to noise
introduced by the RNA amplification process. Of the 14probes representing 13 genes from the Df1 deleted region on
the CodeLink Bioarrays, 11 showed reduced expression on
arrays hybridized with Df1/+;Tbx1+/ target (Table 1), with
a mean level of down-regulation of 0.56-fold, although one
gene (Claudin 5) did not pass the filtering and statistical
analyses applied to the data as a whole (see below). Txnrd2
was represented by two independent probes, both of which
showed significantly reduced expression. Three transcripts
(Tbx1,ES2, andCdcrel1) were expressed below the threshold
detection level. Therefore, the CodeLink microarray platform
was sensitive enough to detect significantly decreased
expression of 9 of 13 haploid genes in the mutant embryos.
Tbx1 had poor probe design as discussed below. Furthermore,
the expected ratios of gene expression in the mutant and wild
type embryos appeared to have been conserved throughout
the RNA amplification process. If the three genes not
detected as expressed above threshold at E9.5 are excluded
from analysis, then 9 of 10 Df1 genes were detected as
significantly down-regulated by our Codelink analysis.
A similar pattern of down-regulated Df1 gene expression
was observed on the Affymetrix MGU74Av2 arrays,
including down-regulation of further genes not represented
on the CodeLink arrays, although the data were more
variable. 11 of 16 probes were expressed above threshold
detection levels and this equated to 10 deleted Df1 genes out
of a possible 13 that were represented on the arrays once
double probe sets had been accounted for. Six of these 10
showed statistically significant down-regulation. Therefore,
Table 2
Genes down-regulated in Df1/+;Tbx1+/ embryos
Genbank accession Gene description CL Affy
Transcription factors
NM_010445 H6 Homeobox 1 (Hmx1) 0.487
D83147 Six2 0.533 *
NM_011041 Paired box gene 9 (Pax9) 0.553 *
NM_010753 Max dimerization protein 4 (Mad4) 0.619
NM_008241 Forkhead Box G1 (FoxG1) 0.63 *
NM_01070 Lim homeobox protein 2 (Lhx2) 0.653 N
AF022078 Dlx-6 0.675
NM_010262 Gastrulation brain homeobox (Gbx2) 0.680
NM_009099 Tripartite motif protein 30 (Trim 30) 0.681
NM_007772 Human immunodeficiency virus type 1 enhancer binding protein 1 (HIVEP1) 0.688
NM_011749 Zinc finger protein 148 0.690
NM_009986 Cut-like 1 (Cutl1) 0.690
NM_010212 Four and a half LIM domains (Fhl2) 0.713
NM_018826 Iroquois-related homeobox 5 (Irx5) 0.717 N
NM_021441 TBP-associated factor TAF1C 0.732 N
NM_010723 Lim only 4 (Lmo4) 0.754 N
NM_08558 Max 0.787 N
Retinoic acid synthesis/metabolism
NM_011921 Aldehyde dehydrogenase family 1, sub-family A4 (Aldh1a4) 0.322 N
NM_007811 Cytochrome P450, 26, retinoic acid (Cyp26a1) 0.472 *
Kinase/kinase regulators
NM_008745 Neurotrophic tyrosine kinase, receptor, type 2 (Ntrk2) 0.613
NM_019505 Diacylglycerol kinase, epsilon (DGKE) 0.670 N
NM_009271 Rous Sarcoma oncogene (Src) 0.685
NM_010139 Eph receptor A2 0.698
GTP binding/related
NM_07485 Aplysia ras-related homolog D (RhoD, Arhd) 0.618
AK_005770 Rho-related BTB-containing 1 (Rhobtb1) 0.642 N
NM_008137 Guanine nucleotide binding protein binding protein, alpha 14 (Gna14) 0.643
AB060553 Nadrin 1 0.709 N
Signal transduction
NM_026835 Membrane-spanning-4 domain, subfamily A, member 6 (Ms4a6d) 0.611 N
NM_009849 Ectonucleoside triphosphate diphosphohydrolase 2 (Entpd2) 0.631
NM_008192 Guanylyl cyclase 2E (Gucy2E) 0.628
NM_023118 Disabled homolog 2 (Dab2) 0.653 *
AK005141 Calcineurin-regulated kringle domain protein (Crkd) 0.674 N
NM_019549 Pleckstrin 0.686 N
AK021164 Frizzled homolog 9 (Fz9) 0.698
U87868 Phosphatidylcholine-specific phospholipase D1b (MPLD1) 0.725
NM_029460 Riken clone: 4930562N12, homology with G protein coupled receptor Gprc2a-rs1 0.729 N
NM_007462 Adenomatous polyposis coli (APC) 0.746
Protease/protease regulators
NM_010374 Granzyme F (Gzmf) 0.217
NM_019471 Matrix metalloproteinase 10 (MMP10) 0.658
NM_011454 Serine Protease Inhibitor 12 (Spi12) 0.686 N
Cell adhesion
NM_009263 Secreted phosphoprotein 1 (Spp1) 0.341
NM_01305 Desmocollin 2 (Dsc2) 0.547
NM_011346 Selectin, lymphocyte (Sell) 0.555
AK017578 Riken clone:5730419 neurexin 1 0.652 N
Cell growth/differentiation-related factors
NM_008960 Phosphatase and tensin homolog (PTEN) 0.573
NM_008046 Follistatin 0.655 *
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Table 2 (continued)
Genbank accession Gene description CL Affy
Cell growth/differentiation-related factors
NM_010756 V-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (MafG) 0.672
NM_010512 Insulin-like growth factor 1 (Igf1) 0.703
NM_016719 Growth factor receptor bound protein 14 (Grb14) 0.711 N
NM_008552 Mas1 oncogene 0.723
NM_053087 Epithelial mitogen (EPGN) 0.740 N
NM_011819 Growth differentiation factor 15 0.770
Apoptosis-related factor
NM_009809 Caspase 1 (Casp14) 0.761
Defense/immunity
NM_010738 Lymphocyte antigen 6 complex (Ly6) 0.169
NM_009139 Small inducible cytokine A6 (ScyA6) 0.644
NM_021337 Superkiller viralicidic activity 2-like (Skiv2l) 0.667
NM_007645 CD37 antigen 0.667
AF126834 Periplakin 0.687
NM_017480 Inducible T-cell co-stimulator (Icos) 0.735
Ion transport
NM_011322 Sodium channel, voltage-gated, type 1, beta polypeptide (Scn1b) 0.635
NM_011323 Sodium channel, voltage gated type VIII, alpha polypeptide (Scn8a) 0.670
NM_080465 Potassium intermediate/small conductance calcium-activated channel (Kcnn2) 0.727 N
NM_022413 Epithelial calcium channel 2 (Ecac2) 0.733 N
NM_011887 Sodium channel, voltage gated type XI, alpha polypeptide (Scn11A) 0.790 N
Structural
NM_013550 Histone 4 0.542
NM_007424 Aggrecan 1 (Agc1) 0.579
M_017379 Tubulin alpha 8 (TubA8) 0.631
NM_016798 PDZ and LIM domain 3 (Pdlim3) 0.654 *
NM_021895 Alpha actinin 4 (Actn4) 0.660
NM_009903 Claudin 4 (Cldn4) 0.664
AK004110 Whirlin (Whrn) 0.667 N
NM_008756 Occludin (ocln) 0.739
Transporter proteins
AK005070 Riken clone: 1300019P08, tricarboxylate transport protein precursor (Ctp) 0.582
NM_010695 Lipocalin 4 (Lcn4) 0.637
Miscellaneous enzymes
NM_013930 Lysine oxoglutarate reductase, saccharine dehydrogenase (Lorsdh) 0.510 *
NM_008085 Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic (GAPDS) 0.597
AK004761 Riken clone: 1200014F22 homolog to lysosomal apyrase-like protein (Lalp70) 0.622
NM_018830 N-Acylsphingosine amidohydrolase 2 (Asah2) 0.656 N
NM_027945 Citrate synthase 0.666
AF117951 Lysly oxidase-like protein 2 0.694 N
NM_010215 Interleukin-four induced gene 1 (Fig1) 0.698
NM_008061 Glucose-6-phosphatase, catalytic (G6pc) 0.698
NM_033037 Cysteine dioxygenase 1, cytosolic (Cdo1) 0.705
NM_101265 Glucosaminyl (N-acetyl) transferase 1 core 2 (Gcnt1) 0.712
NM_028094 Similar to glucuronyl transferase 0.714 N
Miscellaneous genes
AK005423 Amiloride binding protein 1 0.139
NM_011157 Proteoglycan, secretory granule (Prg) 0.277
M35662 Placental lactogen 1 (Pl-1) 0.525
NM_021385 RAD18 0.547 N
NM_013650 Calgranulin A 0.569
NM_009434 Tumor-suppressing subchromosomal transferable fragment 3 (Tssc3) 0.592
NM_009311 Tachykinin 1 (Tac1) 0.638
AA596988 Torsin family 1 member B (Tor1b) 0.652
NM_009593 ATP-binding cassette, sub-family G (white), member 1 (Abcg1) 0.663 *
(continued on next page)
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Table 2 (continued)
Genbank accession Gene description CL Affy
Miscellaneous genes
NM_019576 Transmembrane molecule with thrombospondin module (Tmtsp) 0.702 N
NM_011721 Werner Syndrome homolog (Wrn) 0.705
AK006382 Protein kinase A anchoring protein 0.709 N
NM_024223 Heart LIM protein (Hlp) 0.714
NM_010171 Coagulation factor III (F3) 0.748
Unknown genes
AB052399 DDWMEST62, 0.480 N
AK006639 Riken clone: 1700039D13, hypothetical Cys-rich region/Ig and MHC complex
domain-containing protein
0.521 N
NM_025572 Riken clone: 2610528J11 0.592 N
AK018739 Riken clone: 0610011B16, hypothetical WD-repeat containing protein 0.690 N
AK006489 Riken clone:1700029F22 0.694 N
NM_024230 Riken clone: 1110030K22, hypothetical calponin homology domain-containing protein 0.710 N
AK002581 Riken clone: 0610012C01 0.710 N
AK007215 Riken clone: 1700120F24 0.723 N
AK017189 Riken clone: 5033423007 0.742 N
Genes selected from Affymetrix
NM_008104 Gcm2 0.620
NM_013467 Aldh1a1 0.683
NM_010104 Endothelin 1 (ET-1) 0.713
NM_009237 Sox3 0.734
CL column shows relative expression on CodeLink Uniset Mouse 1 microarray chips hybridized with Df1/+;Tbx1+/ target (averaged across 5 chips). All the
genes listed passed the quantitative and statistical filtering parameters for down-regulation as described in Materials and methods. Genes selected from
Affymetrix were additional genes considered to be of biological interest that were down-regulated on the Affymetrix MGU74Av2 microarrays but not
represented on the CodeLink chips. In the Affy column, * indicates that genes were also down-regulated on the Affymetrix MGU74Av2microarrays, N means
not present on the Affymetrix MGU74Av2 microarrays.
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accuracy than Affymetrix MGU74Av2 arrays.
Gene expression changes in the mutants
Genespring was used to identify non-Df1 genes showing
altered expression in the mutants. For the purposes of this
experiment, and in order not to exclude small yet significant
changes in gene expression, down-regulated genes were
defined as those showing normalized expression of 0.8 or less
on four out of five Codelink chips hybridized with mutant
target. Up-regulated genes were those with normalized
expression of 1.2 or more on four out of five mutant chips
(statistical analyses applied to the resultant gene lists are
described in Materials and methods and were conducted using
information from all arrays). A total of 105 genes in addition to
the Df1 deleted genes showed statistically significant down-
regulated expression on the CodeLink arrays, while 43 genes
were up-regulated. The same analyses applied to the Affyme-
trix data yielded 215 down-regulated genes, and 216 up-
regulated genes. 25% of the genes selected onCodelink passed
filtering on the Affymetrix analysis. The Codelink data are
summarized in Tables 2 and 3, with selected genes identified in
the Affymetrix comparison included if represented on both
arrays, or if they were considered plausible biological
candidates. We concentrated on the Codelink data because of
the improved detection of Df1-deleted genes as compared to
Affymetrix arrays, and the smaller list size of differentiallyexpressed genes which may have reflected greater specificity.
The differentially expressed genes included several tran-
scription factors, proteins involved in the synthesis and
metabolism of retinoic acid, structural proteins, cell adhesion
molecules, and cell signaling factors as well as several
unknown genes/ESTs.
Real-time quantitative RT-PCR analysis of selected target
genes
We carried out real-time quantitative reverse transcrip-
tion-PCR analysis (RTQPCR) on selected genes in order to
confirm the microarray results. The majority of changes in
gene expression seen on the arrays were small, meaning that
a sensitive method of validation was required. To test real-
time PCR as a potential validation method, we first used it
to analyze expression of three of the haploid Df1 genes:
Comt, Cdc45l, and Txnrd2. In agreement with the micro-
array results, these genes showed 2-fold or greater down-
regulation of expression by RTQPCR (Table 4). Further
genes were then selected for PCR validation because of their
biological relevance and/or because differential expression
was seen on both CodeLink and Affymetrix arrays. A
number of genes that were similarly down-regulated on both
Affymetrix and CodeLink arrays also showed reduced
expression by RTQPCR in Df1/+;Tbx1+/ samples (Table
4). Pax9, Foxg1, and Follistatin showed decreases in
expression that correlated well with the microarray results;
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Pdlim3) or smaller (Six2, Dab2) changes in expression. We
were also interested in two genes that were present only on
the Affymetrix chips, Gcm2 and Sox3. Gcm2 is required
early in the developing parathyroid (Gordon et al., 2001), an
organ which is hypoplastic in Tbx1 null mice (Jerome and
Papaioannou, 2001). Interestingly, we observed a far greater
reduction of Gcm2 expression in Tbx1 nulls by RTQPCR
than by microarrays (5-fold as compared to 1.6-fold). Sox3
was marginally reduced. We looked at three genes, Et-1,
Aldh1a1, and Fhl2, where there was disagreement between
the two types of microarray. Although the expression of Et-
1 and Aldh1a1 was reduced somewhat in the mutants on
both types of microarray, the reduction on the CodeLink
arrays was not sufficient to pass through the data filtering
step. For Fhl2, only the CodeLink arrays showed a
decrease. In each case, RTQPCR showed a decrease in
expression, albeit a 20% reduction for Fhl2.
Finally, we looked at genes that showed the largest
increases in expression on the CodeLink arrays, Raldh2
and HoxA5 (increased by 11.5- and 5.5-fold, respectively).
Both genes were also increased on the Affymetrix arrays,
though to a lesser extent. RTQPCR confirmed that both of
these genes were up-regulated in the mutant RNAs. Again,
the PCR results correlated better with the CodeLink results,
with fold increases of 18.7 and 3.5 for Raldh2 and HoxA5,
respectively. Therefore, overall (with the exception of Sox3)
data obtained by RTQPCR confirmed the expression changes
seen on the microarrays.
In situ hybridizations
In situ hybridization served as an independent method
of validating the microarray results, enabling assessment
of qualitative changes in gene expression in Tbx1 null
embryos, as well as comparing the relative intensity of
staining as a measure of expression level. A single mix
of probe and hybridization solution was used to examine
wild type and mutant embryos in adjacent wells of a six
well dish in order to keep experimental conditions as
closely similar as possible between the two groups of
embryos. Analysis of Tbx1 expression as determined by
h-galactosidase activity confirms previous data that Tbx1
lineage cells are still present in Tbx1/ embryos (Figs.
1A,B). Expression is observed in the PE, the ectoderm
over the branchial arches, and the mesodermal cores of
the arches. However, in Tbx1/ embryos, a single zone
of h-galactosidase expression of uniform intensity is seen
in the unsegmented PE of mutants, in contradistinction to
the relative abundance of transcripts in the posterior of
the second and third pouches at this stage. We selected
Pax9, Gcm2, and Gbx2 for in situ analysis because of
their expression in the PE, which overlaps with that of
Tbx1, and their functional role (see below). At E9.5,
Pax9 expression domains include the pharyngeal pouches
and sclerotome (Neubuser et al., 1995; Peters et al.,1998). In agreement with the real-time PCR and micro-
array results, whole-mounts of Tbx1/ embryos at this
stage showed decreased Pax9 transcripts in the pharyng-
eal region (Fig. 1B). Sclerotomal expression was unal-
tered. As the caudal pouches are not formed in the
Tbx1/ embryos, it was necessary to section the
embryos in order to examine Pax9 expression in the
endoderm. Coronal sections showed that expression in the
endodermal cell layer in the Tbx1 nulls was much
reduced compared to wild type embryos, particularly
when comparing the caudal region of the unsegmented
mutant endoderm to pouch III of the wild type (Fig. 1C).
In contrast, Pax1 expression was found to be robust in
Tbx1/ embryos with no evidence of qualitative or
quantitative changes in expression in the PE (Fig. 1D).
Similarly, focussing on the PE, the expression of Foxa2
is qualitatively and quantitatively maintained in this
tissue, even in the more caudal region of the pharynx
(and foregut), where Pax9 expression is most reduced
(Fig. 1E). Hoxa3 was similarly expressed in the PE, but
also in crest derived mesenchyme; expression in both the
PE and crest derived mesenchyme was maintained in
Tbx1/embryos (Fig. 1F), and was quantitatively unaf-
fected as determined by RTQPCR (Table 4).
In order to examine whether Pax9 expression is altered
prior to the appearance of the pharyngeal pouches, we
conducted in situ hybridizations of E8.5 embryos. At this
stage, embryos cannot be correctly genotyped on the basis
of phenotype i.e. there is no obvious tissue loss in Tbx1/
embryos. Pax9 expression was consistently reduced in the
pharyngeal region of E8.5 embryos, although the extent of
expression was broadly equivalent (Figs. 1G,H).
Gcm2 has a very restricted pattern of expression in the
pharyngeal pouches (Gordon et al., 2001). At E9.5, there is
diffuse expression in the 2nd and 3rd pharyngeal pouches,
which becomes confined to the 3rd pouch by E10.5. As
expression of Gcm2 is more distinct at E10.5, we compared
expression in the Tbx1 wild type and mutant embryos at this
stage. Gcm2 expression appeared to be completely absent in
the Tbx1 null embryos by whole-mount (Fig. 1I) at this
stage. Serial sectioning confirmed the absence of Gcm2
expression in the unsegmented endodermal tissue (Fig. 1J).
Thus, although the microarray results implied down-
regulation of Gcm2 in the absence of Tbx1, in situ analysis
showed a complete loss of expression in the null embryos,
more consistent with the RTQPCR data.
In situ hybridizations of E10.5 embryos showed
decreased expression of Gbx2 in the PE in all mutant
embryos analyzed, and a zone of expression in the
posterior portion of the first arch was absent in
approximately half of all mutants (Figs. 1K,Li vs. Liii).
In other embryos, a generalized reduction in expression
(Fig. 1Lii vs. Liv) was observed. At E9.5, Gbx2
expression was not as strong as at E10.5, but a reduction
of expression in the PE and first branchial arch can still
be seen (Fig. 1M). Sections at this stage indicated
Table 3
Genes up-regulated in Df1/+;Tbx1+/ embryos
Accession Gene description CL Affy
Transcription factors
NM_010453 Homeo Box A5 (HoxA5) 5.489 *
AA388194 Cartilage homeoprotein 1 (Cart-1) 2.504 N
AF080623 Terra 2.436 N
NM_010827 MyoR 2.389 *
AK013905 Wilm’s tumor 1 (Wt-1) 2.037
NM_011859 Odd-skipped related 1 (Osr1) 1.921 N
NM_009328 Transcription factor 15 (Tcf15) 1.785
NM_010691 Ladybird-like homeobox 1 (Lbx1h) 1.462 N
Retinoic acid synthesis/metabolism
NM_009022 Aldehyde dehydrogenase family 1, sub-family A2 (Raldh2) 11.499
NM_011303 Retinal short chain dehydrogenase//reductase 1 (Rsdr1) 1.435 *
Signaling
NM_023653 Wnt2 3.256 N
NM_013696 Thyrotropin releasing hormone receptor (Trhr) 2.382
NM_010051 Dickkopf Homolog 1 (Dkk1) 1.978
NM_008791 Purkinje cell protein 4 (Pcp4) 1.940 *
NM_009215 Somatostatin (Smst) 1.931
NM_017400 SH3 domain GRB2-like 3 (Sh3gl3) 1.687 *
NM_023048 Ankyrin repeat and Socs box-containing protein 4 (Asb4) 1.488
NM_008966 Prostaglandin F receptor (Ptgfr) 1.334
NM_007786 Casein kappa (Csnk) 1.284 *
NM_010052 Delta-like homolog 1 (Dlk1) 1.889 *
Proteases
AK003088 Carboxypeptidase A precursor 5.689 N
NM_009619 A disintegrin and metalloprotease domain 3 (Adam3) 1.284
Cell adhesion
NM_011582 Thrombospondin 4 (Thbs4) 1.812 N
NM_015784 Osteoblast-specific factor 2 (Osf2) 1.452 *
NM_007662 Cadherin 15 (Cdh15) 1.413
Ion transport
NM_019510 Transient receptor potential cation channel subfamily
c member 3 (Trpc3)
1.69 N
Muscle contraction regulation
NM_009394 Troponin C2, fast skeletal (Tnnc2) 3.024
NM_011619 Troponin T2, cardiac (Tnnt2) 1.851 *
Miscellaneous enzymes
NM_007482 Arginase 1 (Arg1) 2.741 *
NM_007823 Cytochrome p450 subfamily 4b polypeptide 1 (Cyp4b1) 1.706
AK006357 Novel protein similar to lysozyme C1 1.523 N
AK003894 Hypothetical diphospho-sugar transferase structure containing protein 1.443 N
NM_028089 Cytochrome p450 family 2 subfamily c polypeptide 55 (Cyp2c55) 1.429 N
NM_015801 Neuropathy target esterase (Nte) 1.316 N
NM_007832 Deoxycytidine kinase (Dck) 1.248
Miscellaneous genes
AK020485 Homolog to HGTD-P 2.112 N
NM_010473 Histidine-rich calcium binding protein (Hrc) 1.707
NM_018866 Small inducible cytokine subfamily b, member 13 (Scyb13) 1.69 N
NM_021310 Junction-mediating and regulatory protein (Jmy) 1.376 N
AK008761 F-Box protein 23 (Fbx 23) 1.375 N
AK004017 Androgen down-regulated, Admp 1.384 N
NM_009475 Uterine-specific proline-rich acidic protein (Prap1) 1.354 N
Unknown gene
AK017440 Riken full-length clone: 5530401N18 1.463 N
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Table 4
Real-time quantitative PCR results for selected genes
Gene Df1/+;Tbx1+//wild type ratio
Cdc45l 0.508 T 0.10
Comt 0.515 T 0.01
Txnrd2a 0.330 T 0.03
Aldh1a1 0.386 T 0.05
Cyp26a1 0.360 T 0.01
Dab2 0.790 T 0.07
Eya1 1.540 T 0.36
ET-1 0.560 T 0.13
Fhl2a 0.773 T 0.15
Follistatin 0.720 T 0.05
FoxG1 0.665 T 0.11
Gbx2a 0.423 T 0.09
Gcm2 0.195 T 0.04
Pax9 0.530 T 0.13
Pdzlim3 0.514 T 0.05
Six2 0.796 T 0.12
Sox3 0.936 T 0.12
HoxA3a 1.198 T 0.12
HoxA5 5.134 T 0.72
Raldh2 18.73 T 3.90
Values indicate expression levels in pooled Df1/+;Tbx1+/ RNA samples
from at least four embryo dissections relative to wild type as determined by
real-time quantitative PCR carried out on the Cepheid SmartCycler or aABI
7000 (corrected for GADPH expression, mean of at least three separate
experiments, Tstandard deviation).
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the PE (Fig. 1N).
For Raldh2, a retinaldehyde dehydrogenase responsible
for early embryonic retinoic acid synthesis, the microarray
and real-time PCR results suggested a large increase in
mRNA levels in the mutant embryos. However, by in situ
analysis of E9.5 wild type and Tbx1 mutant mouse embryos,
this did not appear to be the case. At E9.5, Raldh2 is
expressed in the splanchnic mesoderm with a boundary
caudal to the foregut pocket, in the mesenchyme surround-
ing the cervical spinal cord and spinal ganglia, and in the
somites, decreasing with differentiation (Niederreither et al.,
1997, 2003). The level of transcripts in these regions did not
appear to be increased in the mutants; however, we observed
an apparent anterior shift in the splanchnic mesodermal
expression which is likely to account for the microarray
results, these expressing regions being brought into the
dissected area (Fig. 2A). This is confirmed by examination
of sagital sections, where in null embryos the distance from
the anterior border of Raldh2-expressing cells is much
closer to landmarks such as the first branchial arch than in
wild types (Fig. 2B). Null embryos appeared to have
increased Raldh2 expression in a region just anterior to
the first arch in an area where expression could only just beNotes to Table 3:
CL column shows relative expression on CodeLink Uniset Mouse 1 microarray ch
genes listed passed the quantitative and statistical filtering parameters for up-regula
that genes were also up-regulated on the Affymetrix MGU74Av2 microarrays, Ndiscerned in wild type embryos (Fig. 2A). Sections
indicated that these transcripts are in mesenchymal cells
between the forebrain and the dorsal aorta (Fig. 2C).
Analysis of upstream genomic regions for Tbx1 binding
sites
We examined the promoter regions of a number of the
validated target genes for potential Tbx1 binding sites. The
mVISTA program was used to align 5kb of upstream human
and mouse genomic sequences from Gbx2, Pax9, Sox3,
Foxg1, and Six2; it was not possible to align mouse and
human sequence upstream of Gcm2 due to the mouse
sequence still being in unordered pieces. As Tbx1 has been
shown to activate the Fgf10 promoter through a conserved
T-Box binding element (TBE) with the sequence GTGTGA
(Agarwal et al., 2003; Xu et al., 2004), conserved regions of
the above promoters were examined for identical or highly
similar elements. Three conserved TBEs were identified
upstream of Gbx2 (Fig. 3A); site a was located slightly
upstream of the first conserved region, however was fully
conserved between mouse and human. Two potential TBEs
were also found to be conserved upstream of Pax9 (Fig.
3B). In addition, a single conserved site was identified in
both the Foxg1 and Sox3 promoters; however, no TBEs
were found upstream of Six2 (data not shown).Discussion
22q11DS causes a wide range of congenital abnormal-
ities, and in humans is predominantly associated with
hemizygosity for approximately 3Mb of DNA, encoding at
least 35 genes. Chromosome engineering, transgenic
complementation, and gene targeting experiments revealed
that haploinsufficiency of the transcription factor Tbx1 was
sufficient to produce a partial phenocopy of the syndrome.
Tbx1/ embryos have a more severe spectrum of defects,
such as persistent truncus arteriosus, absence of the thymus
and parathyroid glands, and craniofacial dysmorphism, all
observed in 22q11DS patients. Tbx1 acts a transcriptional
activator, and thus identification of downstream targets of
Tbx1 will be vital in elucidating the developmental
pathways affected in 22q11DS. The identification of tran-
scription factor targets represents a considerable challenge
with several techniques having been developed, but no
single methodology representing the approach of choice.
Here, we have used an expression microarray analysis to
identify alterations in the transcriptome of Df1/+;Tbx1+/
transheterozygous mice. This approach has several advan-ips hybridized with Df1/+;Tbx1+/ target (averaged across 5 chips). All the
tion as described in Materials and methods. In the Affy column, * indicates
means not present on the Affymetrix MGU74Av2 microarrays.
Fig. 1. Expression of genes in the pharyngeal endoderm of Tbx1/ mutants. (A) X-gal staining shows expression of Tbx1-lacZ in the pharyngeal endoderm (PE),
ectoderm, and mesodermal core of pharyngeal arches (PA) of Tbx1 heterozygous (+/) and null (/) embryos at E9.5 (coronal sections). In the Tbx1+/ embryo,
staining is stronger in the posterior portions of the second and third pouches but uniform along the unsegmented PE of the null (Tbx1/) embryo (bracketed
regions). Arrows indicate the third arch ectodermal staining in the heterozygous embryo, which is maintained in the null embryo despite the loss of the third arch
itself. (B) Whole-mount in situ hybridization showing Pax9 expression in Tbx1 wild type (+/+) and null embryos at E9.5. Pax9 is expressed strongly in the
pharyngeal pouches of the wild type embryo and more weakly in the sclerotome. In Tbx1/ embryos, Pax9 is down-regulated in the pharyngeal region only.
Coronal sections (C) show more clearly the reduced expression of Pax9 in the caudal, unsegmented PE of the mutant compared to the equivalent region of the wild
type. (D, E, F) In contrast, expression of Pax1 (D), Foxa2 (E), and Hoxa3 (F) is maintained in the PE (Pax1, Hoxa3) and foregut endoderm (Foxa2) of Tbx1/
nulls. Together, these genes cover the areas of PE showing down-regulation of Pax9 and Gbx2 in Tbx1/ embryos. (G, H) Reduced expression of Pax9 is evident
at E8.5 in Tbx1/ mutants, before gross morphological differences arise, although dorsal views of wild type and mutant embryos (H) show that the rostro-caudal
extent of expression is similar (bracketed regions). (I, J) Expression of Gcm2 is lost in Tbx1/ mutants at E10.5. Gcm2 is expressed in a small region of the third
pouch marking the parathyroid specific domain of the common thymus/parathyroid organ primordia (arrowhead in panel I, +/+ embryo). Coronal sections (J) show
that this domain is absent in the PE of the Tbx1/ embryo (oblique sections). (K, L, M, N) Expression of Gbx2 is reduced in the PE and first pharyngeal arch (PA)
of Tbx1/ embryos at E10.5 (K, L) and E9.5 (M, N). (K) Arrowheads indicate mesenchymal expression in the anterior (black arrowhead) and posterior (grey
arrowhead) portions of the first PA; expression in the posterior portion is lost in a proportion of Tbx1/ nulls. (Li– iv) Coronal sections through the first PA. (M,
N) At E9.5 expression of Gbx2 is generally reduced across the pharyngeal region of Tbx1/ nulls, although not in the otic vesicle, ov (M). (N) Coronal sections
show down-regulated expression in the PE of the Tbx1/ mutant at this stage.
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Fig. 2. Raldh2 expression is altered in Tbx1/ mutants. (A) Whole-mounts show strong expression of Raldh2 in the somites and splanchnic mesoderm of a
wild type (+/+) and Tbx1/ (/) E9.5 embryo (both sides of each embryo are shown). In the Tbx1/ mutant, the border of splanchnic mesodermal
expression is shifted anteriorly with respect to other landmarks; double-headed arrows indicate the shorter relative distance between the anterior border of
expression and the otic vesicle (ov) in the mutant. Arrowheads indicate a region of head mesenchyme expressing Raldh2 which by whole-mount is only evident
in the Tbx1/ mutant. (B) Sagittal sections; I – III, pharyngeal arches; H, heart. (C) Serial sagittal sections show the extent of expansion of the head
mesenchyme expression domain in Tbx1/ mutant (lower panels) compared to wild type control (upper panel). The zone of Raldh2-expressing cells is located
between the forebrain (F) and the dorsal aorta (a) and is expanded both laterally and anteriorly in the mutant embryo.
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have the same embryonic phenotype as Tbx1/ embryos,
they provide a good model for absence of Tbx1 expression.
21 genes mapping to the Df1 interval in cis with Tbx1 are
reduced to hemizygosity and we have previously shown that
none of these genes are subject to dosage compensation (i.e.
none of the remaining alleles are regulated back to dizygous
expression levels) (Prescott et al., 2005). Thus, these genes
can be used as internal controls of array and hybridization
quality. The cDNA microarray technology allows a screen of
several thousand potential targets and, if present on the arraysFig. 3. Identification of potential Tbx1-binding sites upstream of Gbx2 and Pax9.
and mouse genomic sequence 5 kb upstream of Gbx2 and Pax9, respectively. Re
indicate conserved potential T-Box binding elements (TBEs). Sequences of the Twith above detection threshold expression levels, the
expression of candidate targets can be interrogated. Dis-
section of carefully staged embryos to derive mRNA from the
Tbx1-expressing region should have increased the signal:
noise ratio. On the other hand, at E9.5, the hypo/aplasia of the
caudal branchial arches inevitably means that some detected
changes will be due to anatomical disruption affecting cell
types not expressing Tbx1. The h-galactosidase knock in
marker indicates that Tbx1-lineage cells are clearly present in
null embryos at E9.5. Thus, genes detected as differentially-
regulated may be downstream of Tbx1 in a developmentalPanels A and B show mVISTA plots (see Materials and methods) of human
gions with greater than 75% nucleotide conservation are shaded. Asterisks
BEs identified in each promoter are shown below.
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require Tbx1 for their proliferation or survival, or they may be
expressed in cell types affected secondarily by the mutation.
To some extent, these issues can be addressed by in situ
expression analysis of the differentially expressed gene in
mutant and control embryos, and by analysis of other genes
known to be expressed in pharyngeal mesendoderm and
branchial arch mesenchyme. Conducting in situ hybrid-
izations on Tbx1/ opposed to Df1/+;Tbx1+/ embryos
will also detect any unsuspected effect the Df1 deletion might
have had on the microarray data. The microarray and in situ
hybridization data presented here identify both quantitative
and qualitative changes in gene expression in Df1/+;Tbx1+/
and Tbx1/ embryos, but independent methods will be
required to identify primary transcriptional targets of Tbx1
from within the group of differentially expressed genes
highlighted in this study.
We found that linear-amplified target derived from
dissections of single embryos could consistently distinguish
between transheterozygote and wild type embryos on the
basis of Df1 gene expression level. This was most evident
for the Codelink arrays, partly because of the number of Df1
genes represented on the array, and partly because of the
choice of probe sequence (some Affymetrix sequences did
not correctly represent the gene in question). Tbx1 itself was
not present on the Affymetrix array, and was below
detection threshold on the Codelink array. This is probably
because the probe chosen represents the less abundant ‘‘a’’
check splice variant (Chieffo et al., 1997) which has a
distinct 3VUTR, rather than the predominant ‘‘c’’ variant
(Gong et al., 2001).
Genes expressed in the pharyngeal endoderm/involved in
thymic and parathyroid morphogenesis
Pax9 was reduced in expression on the Codelink arrays,
and expressed at 53% wild type levels by RTQPCR. The
reduced expression in the PE is unlikely to be due to simple
consequence of defective thymus and parathyroid precursor
development as other genes critical for development of these
structures, which are also expressed in PE and the
pharyngeal arches, are not down-regulated. These genes
include Eya1 (no change on either array set, RTQPCR, or in
situ (data not shown)), Foxa1/2 (see below), Hoxa3 (no
change on either array set, by RTQPCR or by in situ), and
Pax1 (no change Codelink, slight increase on Affymetrix,
no change on in situ). Eya1 is required for the morpho-
genesis of mammalian ear, kidney, thymus, parathyroid, and
thyroid (Xu et al., 2002). Hoxa3/ mice fail to develop a
thymus or parathyroid gland and have heart defects (Manley
and Capecchi, 1995). Pax1 mutants fail to develop para-
thyroid glands and have a small thymus (Wilm et al., 1998);
Hoxa3 and Pax1 have been shown to interact epistatically in
this pathway (Su et al., 2001).
Previous analysis of Pax9 in E9.5 Tbx1/ embryos
demonstrated the presence of Pax9 expression in PE (Hu etal., 2004), and this is confirmed by our in situ hybridizations.
However, Pax9 expression appears reduced in Tbx1 null vs.
wild type PE, particularly in more caudal regions. At this
stage, we detected no change in expression of Pax1 or Foxa2
within the PE, consistent with the microarray analysis.
Furthermore, Pax9 was consistently reduced at E8.5 (11–13
somites) prior to the formation of the caudal pharyngeal
pouches and any gross anatomical abnormalities in Tbx1/
embryos. Pax9/ mice die shortly after birth, most likely as
a consequence of a cleft secondary palate. They lack a
thymus, parathyroid glands, and ultimobranchial bodies,
organs which are derived from the pharyngeal pouches (Peters
et al., 1998). PECAM staining of Pax9/ mutant embryos
(E10.5) has revealed aortic arch patterning defects such as
persisting first aortic artery, although this phenotype is
apparently not completely penetrant (Heiko Peters, personal
communication). Thus, reduction of Pax9 expression levels
in the PE may contribute to the Tbx1/ phenotype, but the
Hoxa3/Pax1-regulated pathway is unlikely to be affected.
Gcm2 was down-regulated in the Affymetrix arrays (not
present on Codelink), and expressed at 20% wt levels by
RTQPCR. The underestimation of relative expression
changes in microarray experiments vs. quantitative PCR
has been commented upon previously (Yoshida et al., 2004)
and is likely to be secondary to increased background noise
and limited sensitivity. Gcm2 is expressed specifically in the
developing second and third pharyngeal pouches at E9.5, and
is further confined to a small domain of the third pouch
endoderm by E10.5, and is a definitive marker of the
parathyroid gland (Gordon et al., 2001). Whole-mount in situ
hybridization of Tbx1/ embryos failed to detect Gcm2
expression in the PE at E10.5, and no expression was seen on
serial sections through the pharyngeal region. At this stage,
Gcm2 is expressed in the common thymic and parathyroid
primordia. These results are similar to those seen in Eya1 and
Hoxa3 null mice, where Gcm2 is absent at E10.5 (Su et al.,
2001), and Pax1 and Pax9 mutants where it is reduced (Xu et
al., 2002). It is possible that the reduction of Gcm2
expression observed is because Tbx1 is required for the
development of progenitors of Gcm2-expressing cells, or that
Tbx1 is required for Gcm2 expression in PE derivatives.
Foxa2 (and Foxc2) has been proposed to act upstream of
Tbx1, and Foxa2 to be regulated by Tbx1 in the pharyngeal
mesoderm (Hu et al., 2004). Foxa1/2 expression was
unchanged on Codelink arrays, and Foxc2 was at 95%
levels. Presumably, the array analysis was insufficiently
sensitive to detect the reduced mesodermal expression.
Foxh1, required for development of the anterior heart field
and its derivatives the right ventricle and outflow tract (von
Both et al., 2004), was detected at below threshold levels on
the arrays. Mef2c, a Foxh1 target in the heart, was expressed
at wild type levels on both arrays (von Both et al., 2004).
Foxg1 expression was reduced to approximately 65% wild
type levels in both arrays and by RTQPCR. Foxg1 interferes
with transforming growth factor beta signaling by associat-
ing with Smad partners, and is expressed in the PE as well
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Hebert and McConnell, 2000). Null mutants die at birth and
have defects of the eye and telencephalon (Xuan et al.,
1995); the cause of death is unknown.
Decreased expression of Gbx2, a gene involved in heart
development
Gbx2 has been studied extensively as a regulator of
midbrain development (Joyner et al., 2000). However, it is
also expressed in the branchial arches and PE (Shamim and
Mason, 1998). We found Gbx2 to have reduced expression
in Tbx1 null embryos. Expression analysis shows that
expression was almost entirely lost from the PE. This is in
contradistinction to the reduced expression of Pax9
described above, and robust expression of Pax1 and Eya1.
In addition, an expression zone in the caudal region of the
first branchial arch and rostral region of the second arch was
reduced or lost. Gbx2 mutants have cardiovascular defects
similar to those seen in 22q11DS: an IAA-B, right aortic
arch and retroesophageal right subclavian artery (Erik
Meyers, personal communication). More rarely, they also
have VSDs and outflow tract malformations. Gbx2 is
regulated by Fgf-8 in the isthmic organizer (Garda et al.,
2001; Ye et al., 2001), of interest given the interaction of
Tbx1 and Fgf-8 controlled pathways (Vitelli et al., 2002b).
The incidence of cardiovascular defects was substantially
increased in Gbx2/ Fgf+/ compound mutants vs.
Gbx2/ alone (Erik Meyers, personal communication).
Thus, Gbx2 is an excellent candidate to be a primary or
secondary target of Tbx1, and cross-breeding of Tbx1 and
Gbx2 mutants should detect any epistatic interaction. Fgf-8
hypomorphic mutants have 22q11DS-like heart defects in
engineered mouse embryos (Frank et al., 2002). In view of
this, the down-regulation of Fgf-10 seen in Tbx1/
embryos, and the epistatic interaction between Tbx1 and
Fgf-8, we interrogated the array data to examine Fgf
expression. Neither Fgf-8 nor Fgf-10 was represented on
the Codelink array and both were below reliable detection
levels on the Affymetrix array.
Bioinformatic analysis of the 5 kb immediately upstream
of Gbx2, Pax9, Sox3, and Foxg1, but not Six2, revealed
potential TBEs similar to a sequence upstream of Fgf10 and
activated by Tbx1. These genes are therefore reasonable
candidates to be direct targets of Tbx1. However, this TBE
was isolated as a Tbx5 binding sequence (Ng et al., 2002)
and true Tbx1 binding sites have yet to be defined. We are
currently conducting a binding site selection experiment and
testing regulation of the respective promoters in transfection
studies.
Retinoic acid metabolism
It is of interest that genes involved in retinoic acid
metabolism had altered expression levels in mutants. Most
notably, in the Df1/+;Tbx1+/ embryos, Raldh2 wasexpressed at 12-fold wild type levels on Codelink arrays
and 18-fold wild type levels by RTQPCR. Whole-mount
in situ hybridizations indicate that this is because the
anterior border of the strong mesodermal Raldh2 expres-
sion is apparently shifted anteriorly. While this is
secondary to an anatomical disruption and does not
represent a real shift in the domain of Raldh2 expression,
some cells will be in closer proximity to this source of
retinoic acid as a result. The increase in Raldh2 expression
in the craniofacial mesenchyme, however, is very unlikely
to be secondary to anatomical disruption. This expression
zone has not been remarked on previously, presumably
because Raldh2 is weakly expressed here in wild type
embryos.
The retinoic acid catabolizing enzyme Cyp26a1 was
expressed at significantly lower levels in both array sets and
by RTQPCR. Cyp26a1 reduces RA signaling, acting as a
sink. Cyp26a1/ embryos have spina bifida, hindgut,
urogenital tract, and heart defects (Abu-Abed et al., 2001;
Sakai et al., 2001), and the caudal dysgenesis phenotype of
Cyp26a1/ embryos can be rescued by hemizygosity of
Raldh2 (Niederreither et al., 2002). Thus, the reduced level
of Cyp26a1 expression may result in a local retinoic acid
toxicity that exacerbates the Tbx1 null phenotype. The
situation with regard to retinoid regulation is complicated by
the down-regulation of other retinoic acid synthesizing
enzymes Aldh1a1 (0.69 on Affymetrix array) and Aldh1a4
(0.32 on Codelink array, and 0.39 by RTQPCR), and the
existence of two other Cyp26 family members (MacLean et
al., 2001; Tahayato et al., 2003). The expression and
functional analysis of the Cyp26 family, and the potential
role of disturbance of retinoid metabolism in Tbx1/
embryos are currently being analyzed further.
Other genes expressed in the branchial arches and
differentially regulated in Df1/+;Tbx1+/ mutants
At E8.5, Six2 is expressed in the foregut and a
mesodermal cell population at the anterior hindbrain level,
this expression become more widespread and including the
branchial arches and the ectoderm between the maxillary
and mandibular arches at E9.5 (Ohto et al., 1998). No gene
targeting has been reported.
Nkx5.3 (Hmx1) is first expressed at E9.5 in the trigeminal
(V) ganglion and 1 day later is seen in the eye, the
mesenchyme underlying the hindbrain, the second branchial
arch, and dorsal root ganglia (Wang et al., 2000). The
requirement for Nxk5.3 during development is unknown,
but it has been shown that Nxk5.3 antagonizes Nkx2.5
activity (Amendt et al., 1999), Nxk2.5 being required for
normal cardiac morphogenesis.
Previous work has shown that the failure of the caudal
pharyngeal arches to form results in ectopic neural crest
migration. The microarray analysis did not uncover any
widespread changes in neural crest-expressed genes. We did
confirm down-regulation of endothelin-1 (Et-1) as previ-
ously reported in the vgo zebrafish model (Piotrowski et al.,
S. Ivins et al. / Developmental Biology 285 (2005) 554–5695682003), with a 56% level by RTQPCR. Et-1 controls the
expression of Dlx family transcription factors, and Dlx6 was
significantly down-regulated in the Codelink arrays, and at
68% wild type levels by RTQPCR. However, no effect of
Ece1 (endothelin converting enzyme) mutations on the
Tbx1+/ phenotype was observed in mouse crosses (Mor-
ishima et al., 2003).
In summary, we have shown that twice linear amplified
target from dissected pharyngeal regions of single E9.5
embryos can distinguish haploid from diploid gene dosage
when the Df1 deletion is present. We detected various
changes in gene expression in embryos nullizygous for
Tbx1 and validated several by real-time quantitative PCR.
Using in situ hybridization, we have confirmed changes in
the expression of Pax9, Gcm2, and Gbx2 in mutant
embryos. Further work is required to determine whether
the diminished expression of these genes is due to the fact
that they are downstream of Tbx1 in a developmental
pathway, or whether particular subsets of cells expressing
these genes are absent or reduced in Tbx1 nulls. This might
be achieved through biochemical analysis of target gene
promoters, breeding of mice with a view to detecting
epistatic interactions, and use of mice with lineage tracers.
Either way, the detection of differential expression of these
genes with a known role in embryogenesis shows that
microarray analysis of mutant embryos is a potentially
useful tool for uncovering genes involved in the develop-
ment of specific structures. Extending the analysis to
microarrays containing more genes of unknown function
could identify novel genes acting in these pathways.Acknowledgments
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